AR045263A1 - Metodo, kit y composicion farmaceutica para tratar infecciones virales - Google Patents

Metodo, kit y composicion farmaceutica para tratar infecciones virales

Info

Publication number
AR045263A1
AR045263A1 ARP040102894A ARP040102894A AR045263A1 AR 045263 A1 AR045263 A1 AR 045263A1 AR P040102894 A ARP040102894 A AR P040102894A AR P040102894 A ARP040102894 A AR P040102894A AR 045263 A1 AR045263 A1 AR 045263A1
Authority
AR
Argentina
Prior art keywords
ribavirin
interferon
antioxidant
protective agent
membrane protective
Prior art date
Application number
ARP040102894A
Other languages
English (en)
Original Assignee
Smith Howard J & Ass Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Howard J & Ass Pty Ltd filed Critical Smith Howard J & Ass Pty Ltd
Publication of AR045263A1 publication Critical patent/AR045263A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método de terapia farmacéutica que comprende la co-administración de cualquier forma de interferón o cualquier derivado del mismo con una dosis baja de ribavirina (inferior a 400 mg/día o inferior a 6 mg/kg/día, o compuesto relacionado, donde la ribavirina o compuesto relacionado provee un nivel de sangre clínicamente efectivo en la circulación portal pero un nivel de sangre menos del clínicamente efectivo en la circulación periférica, para proveer de este modo un efecto sistemático de interferón a través de todo el cuerpo pero un efecto selectivo de ribavirina en el hígado. El método provee además para la co-administración de cualquier forma de interferón o cualquier derivado del mismo con una dosis elevada de ribavirina (preferentemente desde 400-800 mg/día), o compuesto relacionado, donde la ribavirina o compuesto relacionado se administra como una formulación de liberación lenta tal que la misma provee además una respuesta virológica sostenida en un paciente y efectos secundarios reducidos. El método provee asimismo para la co-administración de un antioxidante u otro agente protector de membrana con tanto el interferón como la ribavirina tal que la actividad hepatoprotectora del antioxidante u otro agente protector de membranas complementa el efecto virucidal del interferón y ribavirina. El antioxidante u otro agente protector de membrana se puede administrar como una formulación sistemática o como una formulación hepático-selectiva de baja dosis y de liberación lenta. Reivindicación 32: El uso de una cantidad terapéuticamente efectiva de interferón con una dosis baja de ribavirina y opcionalmente un antioxidante u otro agente protector de membrana en la preparación de un medicamento para tratar infecciones virales en un paciente. Reivindicación 33: Un kit para uso en el tratamiento de infecciones virales caracterizado porque comprende una cantidad terapéuticamente efectiva de interferón en combinación con ribavirina y opcionalmente un antioxidante u otro agente protector de membrana como una formulación de liberación lenta. Reivindicación 43: Una composición farmacéutica para el tratamiento de infecciones virales en un paciente caracterizado porque comprende una cantidad terapéuticamente efectiva de interferón conjuntamente con una dosis baja de ribavirina y opcionalmente un antioxidante u otro agente protector de membrana.
ARP040102894A 2003-08-13 2004-08-12 Metodo, kit y composicion farmaceutica para tratar infecciones virales AR045263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49482803P 2003-08-13 2003-08-13

Publications (1)

Publication Number Publication Date
AR045263A1 true AR045263A1 (es) 2005-10-19

Family

ID=34193246

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102894A AR045263A1 (es) 2003-08-13 2004-08-12 Metodo, kit y composicion farmaceutica para tratar infecciones virales

Country Status (15)

Country Link
US (1) US20070202078A1 (es)
EP (1) EP1660116A4 (es)
JP (1) JP2007501806A (es)
CN (1) CN1835765A (es)
AR (1) AR045263A1 (es)
AU (1) AU2004264255A1 (es)
BR (1) BRPI0413474A (es)
CA (1) CA2535451A1 (es)
CL (1) CL2004002030A1 (es)
IL (1) IL173630A0 (es)
NO (1) NO20060651L (es)
NZ (1) NZ545159A (es)
RU (1) RU2371195C2 (es)
WO (1) WO2005016370A1 (es)
ZA (1) ZA200601181B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1847256B (zh) * 2005-04-13 2011-06-15 长春华普生物技术有限公司 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用
WO2006131790A2 (en) * 2005-06-09 2006-12-14 Flamel Technologies Oral ribavirin pharmaceutical composition
CN101848727A (zh) * 2007-09-05 2010-09-29 尼古拉·叶夫根尼耶维奇·沙图诺夫斯基 脱铁乳铁蛋白组合物及其用于治疗病毒性丙型肝炎的方法
WO2009046369A2 (en) * 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
MY152824A (en) * 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
EP2364098B1 (en) * 2008-12-16 2016-10-12 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
AU2011330701A1 (en) 2010-11-19 2013-07-04 Venus Remedies Limited Novel conjugates for targeted drug delivery
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3222259A (en) * 1963-10-25 1965-12-07 Ethyl Corp Flare stack with a liquid seal
JPS5439143Y2 (es) * 1976-04-16 1979-11-20
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
EP1136075B1 (en) * 1997-09-21 2003-01-15 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
BR9910505A (pt) * 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
AU762395B2 (en) * 1998-10-16 2003-06-26 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CN1355708A (zh) * 1999-04-19 2002-06-26 先灵公司 包含利巴韦林与抗氧化剂的hcv联合治疗
AU2001255495A1 (en) * 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CA2372987A1 (en) * 2001-12-11 2003-06-11 Thomas R. Wiseman Method of disposal of liquid from gas wells

Also Published As

Publication number Publication date
EP1660116A1 (en) 2006-05-31
WO2005016370A1 (en) 2005-02-24
US20070202078A1 (en) 2007-08-30
NO20060651L (no) 2006-05-02
CA2535451A1 (en) 2005-02-24
ZA200601181B (en) 2007-04-25
CL2004002030A1 (es) 2005-06-03
JP2007501806A (ja) 2007-02-01
RU2006107566A (ru) 2007-09-20
IL173630A0 (en) 2006-07-05
AU2004264255A1 (en) 2005-02-24
RU2371195C2 (ru) 2009-10-27
CN1835765A (zh) 2006-09-20
NZ545159A (en) 2009-03-31
EP1660116A4 (en) 2008-04-30
BRPI0413474A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
JP2005501110A5 (es)
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
BRPI0418157A (pt) terapêutica de tumores alogênicos
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
JP2003528919A5 (es)
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
MX9304197A (es) Nuevo uso de dimero de lisozina y composiciones que lo contienen.
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
TR200103144T2 (tr) Yeni bileşikler
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico

Legal Events

Date Code Title Description
FB Suspension of granting procedure